Therefore, our results support the hypothesis that LncRNAs are functional participants in therapy resistance/sensitivity to cancer drugs, and target‐gene therapies ‘EGFR/AKT/ERK/mTOR’ [47]. The gene discussed is MTOR; the disease is cancer.